CORK, Ireland--(BUSINESS WIRE)--Tibotec Pharmaceuticals, Ltd. announced today that the European Commission has granted a conditional marketing authorisation for PREZISTA™ (darunavir, also known by the investigational compound number TMC114), a protease inhibitor for the treatment of HIV-1 infected patients.
